STOCK TITAN

Theravance Bioph - TBPH STOCK NEWS

Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.

Overview of Theravance Biopharma Inc

Theravance Biopharma Inc (NASDAQ: TBPH) is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. With a solid foundation built on internally discovered product candidates and strategic partnerships, the company has positioned itself as a key player in addressing critical unmet needs in the treatment of respiratory and neurological disorders. Utilizing advanced research methodologies and precision medicine approaches, Theravance Biopharma aims to maximize therapeutic efficacy while minimizing systemic side effects.

Core Business and Product Portfolio

At its core, Theravance Biopharma invests heavily in the development of small-molecule drugs designed for organ-selective targeting. This strategy is exemplified by its FDA-approved product, YUPELRI (revefenacin) inhalation solution, which is the first and only once-daily nebulized long-acting muscarinic antagonist (LAMA) approved for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The company’s approach in leveraging organ-selectivity not only underpins its ability to deliver sustained improvements in pulmonary function but also highlights its commitment to addressing patient-specific needs through enhanced treatment outcomes.

Innovative Research and Development Strategy

Theravance Biopharma distinguishes itself through a robust, internally focused research and development platform. The company pioneers a new generation of small molecule drugs by applying its expertise in organ-selectivity to target diseases biologically. This approach is particularly significant in the field of inflammation and immunology where therapeutic indices can be expanded, thereby maximizing benefits while reducing systemic exposure. In addition to YUPELRI, the company is advancing a pipeline of promising product candidates, including ampreloxetine—an investigational agent developed as a once-daily norepinephrine reuptake inhibitor intended to manage symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy (MSA).

Strategic Collaborations and Market Position

Theravance Biopharma’s operational strategy is enhanced by strategic collaborations with other pharmaceutical companies. These partnerships not only complement the company’s internal discovery efforts but also provide additional avenues to accelerate clinical development, expand market reach, and optimize commercialization strategies. The unique collaboration dynamics, such as those with global commercial partners, reinforce the company’s capacity to navigate the competitive landscape and address market challenges effectively, making it a significant entity within the biopharmaceutical sector.

Expertise and Industry Credibility

The company’s demonstrated ability to innovate in the field of organ-selective medicine reflects deep scientific expertise and rigorous research methodologies. By combining academic research, clinical insights, and regulatory know-how, Theravance Biopharma has established a reputation for both innovation and reliability in its therapeutic niche. The consistent focus on delivering measurable clinical benefits, backed by peer-reviewed studies and rigorous clinical trial designs, further enhances its authority within the competitive landscape of respiratory and neurological therapeutics.

Comprehensive Business Model and Value Proposition

Theravance Biopharma’s business model revolves around the development and commercialization of a targeted portfolio that maximizes therapeutic efficacy while addressing market needs through innovative medicine. The company’s dual focus on an approved, commercially successful product and a robust pipeline of candidate drugs positions it well within its market segment. Although complex market dynamics and regulatory challenges exist, its disciplined approach to research and clinical development reinforces its stand as a scientifically driven enterprise dedicated to creating medicines that make a difference.

Investor and Market Insights

For investors and market researchers, Theravance Biopharma represents a blend of innovative research coupled with a commercially validated product. Its trajectory showcases an interplay between internally driven discovery and collaborative strength, which is reflected in its ever-expanding clinical developments and its focused approach toward addressing diseases with significant unmet patient needs. The company continually refines its research and development strategies, ensuring that its product portfolio remains both relevant and robust in an evolving therapeutic landscape.

Rhea-AI Summary
Theravance Biopharma, Inc. (TBPH) to participate in CNS Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference. Senior management to host one-on-one meetings. Webcast available on Theravance.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
conferences
-
Rhea-AI Summary
Theravance Biopharma, Inc. (TBPH) will release its Q4 and full year 2023 financial results on Feb 26, 2024, followed by a conference call and webcast. Investors can join the call via phone or web to get updates on the company's performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
conferences earnings
-
Rhea-AI Summary
Theravance Biopharma, ticker symbol TBPH, announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for maintenance treatment of COPD. The study compared YUPELRI to Spiriva HandiHaler in adults with severe to very severe COPD and suboptimal peak inspiratory flow rate (PIFR). While the primary endpoint was not met, YUPELRI demonstrated similar lung function improvement and safety profile consistent with previous clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.98%
Tags
none
Rhea-AI Summary
Theravance Biopharma, Inc. (NASDAQ: TBPH) appoints Jeremy Grant to its Board of Directors, enters into a cooperation agreement with Irenic Capital, and reaffirms its commitment to maximizing shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
management
-
Rhea-AI Summary
Theravance Biopharma, Inc. (NASDAQ: TBPH) will have its management team, including CEO Rick E Winningham and CFO Aziz Sawaf, holding investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference from January 8-11, 2024, in San Francisco, CA. Investors can request a one-on-one meeting with the management team by contacting investor.relations@theravance.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary
Theravance Biopharma, Inc. (NASDAQ: TBPH) announced a new anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) at the 34th International Symposium on The Autonomic Nervous System. The analysis underscores the clinical relevance of the Orthostatic Hypotension Symptom Assessment domain of the Orthostatic Hypotension Questionnaire, supporting its use as a primary endpoint in clinical studies. Key observations from the analysis include the identification of clinically meaningful thresholds for improvement and worsening of the OHSA composite score, as well as the demonstration of a 1.6 point benefit of ampreloxetine relative to placebo in MSA patients during the randomized withdrawal period of Study 170.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences
Rhea-AI Summary
Theravance Biopharma, Inc. (NASDAQ: TBPH) to participate in Fireside Chat at Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences
-
Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) and Theravance Biopharma, Inc. (NASDAQ: TBPH) announce positive Phase III results for YUPELRI in China, demonstrating efficacy and safety for COPD patients. The study shows a statistically significant increase in trough FEV1 compared to placebo, supporting a regulatory filing in China in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
-
Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) and Theravance Biopharma, Inc. (NASDAQ: TBPH) announce positive results from the YUPELRI Phase III clinical trial in China, demonstrating efficacy and safety for COPD patients. Top-line results show a statistically significant increase in trough FEV1 versus placebo, supporting a regulatory filing in China in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
Rhea-AI Summary
Theravance Biopharma (TBPH) reports record high net sales of $58.3 million for YUPELRI in Q3 2023, with a 9% increase from Q3 2022. The company expects to complete a $325 million capital return program by year-end, having returned $30.8 million via share repurchases during Q3 2023 and $294.6 million since inception through quarter end. The Q3 2023 GAAP Net Loss was $9.0 million and Non-GAAP Loss was $0.7 million. Áine Miller, Ph.D. has been promoted to SVP of Development, while Richard A. Graham, Ph.D. will remain through February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags

FAQ

What is the current stock price of Theravance Bioph (TBPH)?

The current stock price of Theravance Bioph (TBPH) is $9.01 as of April 2, 2025.

What is the market cap of Theravance Bioph (TBPH)?

The market cap of Theravance Bioph (TBPH) is approximately 438.1M.

What is Theravance Biopharma's core business?

Theravance Biopharma focuses on the discovery, development, and commercialization of organ-selective medicines. Its strategy centers on creating small-molecule drugs that maximize efficacy and minimize systemic side effects.

What key products does the company offer?

The company’s flagship product is YUPELRI, an FDA-approved, once-daily nebulized long-acting muscarinic antagonist for COPD maintenance. Additionally, it is advancing ampreloxetine in its pipeline for neurological indications.

How does Theravance Biopharma generate revenue?

Revenue is primarily generated through the commercialization of its approved product, YUPELRI, and through strategic collaborations that bolster its clinical development and market reach.

What distinguishes its research and development strategy?

Theravance Biopharma applies organ-selective targeting to enhance the therapeutic index of its medicines. Its robust internal discovery engine, combined with strategic partnerships, underpins its innovative R&D approach.

How does the company maintain its industry credibility?

The company leverages decades of research, peer-reviewed clinical studies, and rigorous trial designs, all of which reinforce its scientific expertise and build trust within the medical and investor communities.

What are the potential challenges it faces?

Challenges include navigating regulatory requirements, managing clinical trial complexities, and addressing competitive pressures. However, its strategic collaborations and focused R&D provide a strong foundation to meet these challenges.
Theravance Bioph

Nasdaq:TBPH

TBPH Rankings

TBPH Stock Data

438.06M
46.39M
6.22%
93.64%
7.54%
Biotechnology
Pharmaceutical Preparations
Link
United States
GEORGE TOWN, GRAND CAYMAN